Latest Breaking News On - Investigator sponsored phase - Page 2 : comparemela.com

BioVie Inc Interview to Air on Bloomberg U S on the RedChip Money Report(R)

BioVie Inc Interview to Air on Bloomberg U S on the RedChip Money Report(R)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaCompany phaseBiovie incBiovie or companyRedchip companies incRedchip companiesRedchip money reportInvestigator sponsored phaseInvestor relationsDiscovering tomorrowBlue chipsWall streetChip companies

Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates

- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia Presented at European Hematology Association Meeting 2022 - - Positive Data from the Ongoing Phase 2 Study. | August 12, 2022

United statesSouth san franciscoWashington schoolLaurence wattsHugh young rienhoff jrJoseph hiattRafael santana davilaCompany nasdaqNational cancer instituteCanale communicationsEuropean hematology associationResearch development rd expensesAmerican society of hematologyGlobenewswire incImago biosciences incFred hutchinson cancer center hutch

Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today.

United statesUnited kingdomNew zealandMatthew deyoungDavid wiseDouglase onsiOncologist at perlmutter cancer centerLangone healthAmerican society of clinical oncologyBeigene ltdPrnewswire leap therapeutics incSecurities exchangeLeap therapeutics incPerlmutter cancer centerClinical oncologyAnnual meeting

Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today.

United statesUnited kingdomNew zealandMatthew deyoungDavid wiseDouglase onsiOncologist at perlmutter cancer centerLangone healthAmerican society of clinical oncologyBeigene ltdPrnewswire leap therapeutics incSecurities exchangeLeap therapeutics incPerlmutter cancer centerClinical oncologyAnnual meeting